Skip to main content
. 2018 Sep 24;28(5):273–284. doi: 10.1089/nat.2018.0722

FIG. 4.

FIG. 4.

VSVluc-EboV GP infection is reduced in the presence of LNA ASOs that inhibit NPC1 expression. NPC1 LNA20 and the negative control LNA24 were transfected into HeLa cells, which were then infected with a VSV vector encoding Ebola-GP (VSVluc-EboV GP) after 48 h. VSVluc-EboV GP luciferase levels were measured after 48 h. VSVluc-EboV GP luciferase levels decreased significantly in a dose-dependent manner after treatment with 25, 50, and 100 nM of NPC1-targeting LNA20. LNA20 data are presented relative to LNA24 (control LNA). NPC1 siRNA used as positive control for NPC1 knockdown also showed significant decrease in VSVluc-EboV GP luciferase levels. Negative control LNA ASO and nontargeting siRNA controls did not reduce VSVluc-EboV GP luciferase levels. IC50 for LNA20 was calculated and provided in Supplementary Table S2. **P < 0.01, ***P < 0.001. Experiments were performed in three biological replicates (triplicate). GP, glycoprotein; VSV, vesicular stomatitis virus.